This site may receive compensation from the provider linked above. Full disclosure.
Weight loss and GLP-1 providers currently serving Prentiss County, Mississippi — sourced from Google Business listings.
Weight loss service
1204C N 2nd St, Booneville, MS 38829
Weight loss service
2005 N 2nd St, Booneville, MS 38829
Nutritionist
511 N 2nd St, Booneville, MS 38829
Business listings sourced from Google Maps. Information may not be current.
GLP-1 telehealth services are available to residents of all communities in Prentiss County, Mississippi. Select your city for local information.
Prentiss County is a county in Mississippi with a population of approximately 25,126 residents. Our telehealth platform connects patients across all communities in Prentiss County with board-certified physicians who can prescribe FDA-approved GLP-1 medications online. Mississippi holds the alarming distinction of being the most obese state in America at 39.5%, and has ranked at or near the top for over two decades. The Mississippi Delta — one of the poorest regions in the US — has obesity rates exceeding 45% in some counties.
GLP-1 receptor agonists — including semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) — are clinically proven weight loss medications. Mississippi's 39.5% adult obesity rate is the highest in the nation (CDC 2023). Approximately 650,000 Mississippians have diagnosed diabetes — the highest rate per capita in the US. Patients in Prentiss County can now access these treatments through a simple online consultation, without the need to travel to an in-person clinic.
Access Ozempic, Wegovy, Mounjaro, and Zepbound — all FDA-approved GLP-1 medications proven to support significant weight loss in clinical trials.
All prescribing physicians in our network hold active Mississippi medical licenses. Consultations comply with Mississippi telehealth law (Mississippi Code § 73-25-34).
Our simple 3-step process makes getting a GLP-1 prescription easy for Prentiss County residents.
GLP-1 telehealth services are available across all Mississippi counties. Browse neighboring counties below.
Explore GLP-1 telehealth availability across Mississippi's major cities.
Yes. Mississippi law permits telehealth prescriptions for GLP-1 medications after a proper clinical evaluation under Mississippi Code § 73-25-34. Our network of Mississippi-licensed physicians can complete your consultation online and send a prescription to your preferred pharmacy in Prentiss County or arrange home delivery.
Patients in Prentiss County can be prescribed semaglutide (Ozempic®, Wegovy®), tirzepatide (Mounjaro®, Zepbound®), and liraglutide (Saxenda®) — all FDA-approved GLP-1 receptor agonists indicated for weight management. Your physician will recommend the most appropriate option based on your health profile.
Consultation fees vary by provider, typically ranging from $0 to $199 for the initial visit. Medication costs depend on insurance coverage, manufacturer savings programs, and pharmacy choice. Many patients in Mississippi qualify for significant savings through patient assistance programs.
After completing your online health assessment, most patients in Prentiss County receive a physician response within 24–48 hours. If approved, your prescription can be sent to a pharmacy near you in Prentiss County or shipped directly to your home within 2–5 business days.
Prentiss County has several local weight loss clinics and medical practices that may offer GLP-1 treatments in person. However, our telehealth service provides the same quality of care from the convenience of your home, with licensed Mississippi physicians available to patients throughout Prentiss County.
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
